Table 2 Summary of initial antifungal treatment in patients with proven and suspected invasive candidiasis
From: Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study
Antifungal treatment | SAT for proven invasive candidiasis N = 291 | SAT for suspected invasive candidiasis N = 544 |
|---|---|---|
Monotherapy | 287 (98.6 %) | 541 (99.5 %) |
Polyenes | 6 (2.1 %) | 6 (1.1 %) |
Amphotericin B deoxycholate | 0 | 3 |
Liposomal amphotericin B | 4 | 3 |
Amphotericin B lipid complex | 2 | 0 |
Azoles | 99 (34.5 %) | 248 (45.8 %) |
Fluconazole | 99 | 244 |
Voriconazole | 0 | 4 |
Echinocandin | 182 (63.4 %) | 287 (53.0 %) |
Caspofungin | 160 | 252 |
Micafungin | 20 | 34 |
Anidulafungin | 0 | 1 |
Flucytosine | 0 | 0 |
Combination therapy | 4 | 3 |
Liposomal amphotericin B and flucytosine | 0 | 2 |
Caspofungin and fluconazole | 2 | 0 |
Caspofungin and voriconazole | 1 | 0 |
Caspofungin and flucytosine | 1 | 0 |
Amphotericin B deoxycholate and micafungin | 0 | 1 |